Goldman Sachs
CGEM icon

Goldman Sachs’s Cullinan Oncology CGEM Stock Holding History

Goldman Sachs’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.47M Sell
455,449
-266,415
-37% -$3.42M ﹤0.01% 3457
2025
Q4 		$7.47M Sell
721,864
-262,096
-27% -$2.36M ﹤0.01% 3366
2025
Q3 		$5.83M Buy
983,960
+281,822
+40% +$2.06M ﹤0.01% 3505
2025
Q2 		$5.29M Buy
702,138
+53,181
+8% +$427K ﹤0.01% 3356
2025
Q1 		$4.91M Sell
648,957
-36,417
-5% -$349K ﹤0.01% 3368
2024
Q4 		$8.35M Sell
685,374
-15,178
-2% -$218K ﹤0.01% 2969
2024
Q3 		$11.7M Buy
700,552
+247,765
+55% +$4.39M ﹤0.01% 2560
2024
Q2 		$7.9M Buy
452,787
+283,420
+167% +$6.03M ﹤0.01% 2731
2024
Q1 		$2.89M Buy
169,367
+41,052
+32% +$634K ﹤0.01% 3571
2023
Q4 		$1.31M Buy
128,315
+42,204
+49% +$374K ﹤0.01% 4228
2023
Q3 		$779K Sell
86,111
-15,316
-15% -$160K ﹤0.01% 4417
2023
Q2 		$1.09M Sell
101,427
-78,393
-44% -$833K ﹤0.01% 4291
2023
Q1 		$1.84M Buy
179,820
+11,930
+7% +$132K ﹤0.01% 3934
2022
Q4 		$1.77M Sell
167,890
-158,860
-49% -$1.93M ﹤0.01% 4032
2022
Q3 		$4.19M Buy
326,750
+161,441
+98% +$2.18M ﹤0.01% 3288
2022
Q2 		$2.12M Buy
165,309
+81,658
+98% +$926K ﹤0.01% 3998
2022
Q1 		$876K Buy
83,651
+3,250
+4% +$43.9K ﹤0.01% 4929
2021
Q4 		$1.24M Sell
80,401
-77,100
-49% -$1.54M ﹤0.01% 4658
2021
Q3 		$3.56M Buy
157,501
+145,148
+1,175% +$3.88M ﹤0.01% 3659
2021
Q2 		$318K Sell
12,353
-43,707
-78% -$1.34M ﹤0.01% 5484
2021
Q1 		$2.34M Buy
+56,060
New +$2.28M ﹤0.01% 3838

Other funds holding CGEM

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Goldman Sachs's CGEM Position: Q1 2026 in Review

Goldman Sachs reduced its Cullinan Oncology (CGEM) stake by 37% in Q1 2026, selling an estimated $3.42M and leaving 455,449 shares worth $6.47M. The position accounts for ﹤0.01% of the portfolio, ranked #3457.

Goldman Sachs first reported a position in CGEM in Q1 2021 and has held it in 21 quarters since. The position peaked at $11.7M in Q3 2024. 174 funds tracked by Wall St. Rank hold CGEM as of Q1 2026.

  • Goldman Sachs held 455,449 shares of Cullinan Oncology worth $6.47M as of Q1 2026.
  • Goldman Sachs sold 266,415 Cullinan Oncology shares in Q1 2026, an estimated $3.42M.
  • Cullinan Oncology made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3457 holding.
  • Goldman Sachs first reported a position in Cullinan Oncology in Q1 2021 and has held it in 21 quarters since.
  • Goldman Sachs's Cullinan Oncology position peaked at $11.7M in Q3 2024.
  • 174 funds tracked by Wall St. Rank held Cullinan Oncology as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.